Pharmacy Growth Collaborative (October 14-16): Evaluating the ROI of Your Fall Travel

If I hear one more stakeholder call a conference a "must-attend," I’m going to personally revoke their corporate card. In my 11 years of building commercial strategy portfolios for mid-size biotechs and top-15 pharma teams, I’ve seen thousands of dollars—and precious Q4 time—evaporated by teams attending events because they were “always on the calendar.”

Let’s get one thing clear: conferences are a tool, not a badge of honor. You should be selecting events based on your commercial objectives, not the glossy brochures sent by event marketing firms. The Pharmacy Growth Collaborative (October 14-16) is coming up, and before your team packs their bags, we need to strip away the marketing fluff and look at what this event actually delivers in terms of actionable market access and commercial execution.
The “Goal-First” Conference Audit
My strategy is simple: If you cannot articulate a specific, measurable outcome you need from a meeting, you shouldn't be there. Most of these events look big but do absolutely nothing for long-term patient adoption. We are looking for three distinct signals: high-level partnering, clinical commercialization, and the harsh reality of formulary access.

When assessing the Pharmacy Growth Collaborative, we have to contrast it against the industry heavyweights:
BIO Partnering Platform: The gold standard for licensing and pipeline expansion. Fierce Pharma Week: The tactical center for commercial execution and competitive intelligence. The Health Management Academy (THMA): The definitive environment for understanding health system adoption and the true gatekeepers of the formulary. The Strategic Pillars of the October 14-16 Focus
To determine if the Pharmacy Growth Collaborative is worth your seat at the table, you need to map it against the challenges currently stalling your growth. Based on the current agenda landscape, here is how the event stacks up against the critical business drivers.
1. Partnering and Licensing: The Summer Anchor
If your goal is inorganic growth or sourcing assets to build out your specialty pharmacy portfolio, you are likely already using the BIO Partnering platform. The Collaborative needs to be evaluated based on whether it offers "second-order" partnering—the kind where you aren't just signing a deal, but finding the regional health systems that are willing to serve as pilot sites for your new asset. If the event is just a networking mixer without a structured, data-backed partnering interface, keep your expectations low.
2. Commercial Execution and Competitive Intelligence
Drawing from the rigor of Fierce Pharma Week, the Collaborative should focus on the "how." Are they discussing the tactical nuances of launch, or are they just rehashing macro-trends? If you are attending for commercial intelligence, look for sessions that dissect competitor moves in the digital pharmacy space or shifts in patient journey mapping. If you leave the room without a clear idea of how to counter a competitor's messaging, you’ve wasted your time.
3. Health System Adoption and Formulary Reality
This is where most commercial teams fail. They think they’re selling to doctors; in reality, they are fighting for space on a worldpharmatoday https://www.worldpharmatoday.com/news/must-attend-pharmaceutical-industry-conferences-in-2026-and-beyond/ P&T committee. The Health Management Academy (THMA) forums are essential because they force pharma leaders to hear the cold, hard math of health system budgets. Does the Pharmacy Growth Collaborative offer that same “look-in-the-eye” access to health system leadership? If it doesn’t address the P&T committee process, you aren't learning about growth—you’re learning about marketing theory.
Critical Decision Matrix: The Tactical Deep Dive
To help you navigate the agenda, I have put together a table based on the key themes you need to address. Use this to determine if the specific breakout sessions are worth your presence.
Focus Area The "Vanity" Approach (Avoid) The "Needle-Mover" Approach (Pursue) 340B Strategy General updates on federal legislation. Specific models for managing 340B contract pharmacy compliance in light of recent manufacturer restrictions. Ambulatory Infusion Debating the pros/cons of infusion. Financial modeling: "Build vs. Partner" analysis for health systems looking to recapture infusion spend. Formulary Access Broad discussions on "getting on the list." Tactical insights into value-based contracting and specific barriers for your therapy class within IDNs. Addressing the "Build vs. Partner" Dilemma
One of the most frequent questions I get from BD leads is whether they should push for an in-house ambulatory infusion build or seek a strategic partner. This is a classic "Buy vs. Build" trap. If you attend the Pharmacy Growth Collaborative, you should be looking for data on how health systems are currently evaluating their own risk profiles in this area. A system that is currently “building” its internal capacity is a system that will likely block your external specialty pharmacy access. Your sales strategy must pivot accordingly.
The 340B Strategy Reality Check
Let's be clear: 340B is no longer a "back-office" issue. It is a commercial barrier. If the agenda at this Collaborative treats 340B as a legal issue rather than a pricing and distribution strategy issue, you are looking at the wrong sessions. Find the tracks that discuss how 340B visibility (or lack thereof) is impacting your gross-to-net calculations and your ability to place products in the systems that actually treat your patient population.
A Note on Logistics and Investment
In the interest of full transparency and avoiding the usual "hand-wavy" conference marketing: I have not been provided with registration costs, ticket prices, or specific hotel rates for the October 14-16 Pharmacy Growth Collaborative.

Do not let the lack of transparency on the website be a deterrent—or an excuse. Whether the ticket is $500 or $5,000 is irrelevant if you don't know the ROI. Before you pull the trigger, follow this simple checklist:
Map the Attendees: Use LinkedIn to see if the specific health system decision-makers you are currently targeting are attending. If they aren't, you aren't. Review the Speaker List: Are these practitioners, or are they consultants selling a vendor deck? You want practitioners. Define the Q4 Goal: Are you trying to secure a formulary slot for January? Are you trying to find a distribution partner? If the conference agenda doesn't explicitly touch these, don't go. The "Night Before" Test: Can you list three people you *must* speak to by the end of the conference? If not, you haven't done enough pre-work. The Verdict
The Pharmacy Growth Collaborative has the potential to be a high-leverage event if you approach it with the rigor of a commercial strategist. Avoid the "must-attend" hype. Instead, treat it like a mission: extract the intelligence on 340B, clarify your ambulatory infusion messaging, and leave the conference with a list of contacts who actually have the power to approve your product in their system.

If the event doesn't move your adoption numbers or improve your pipeline velocity by the end of the year, it was just an expensive networking trip. Don’t fall into the trap of confusing "busy" with "productive."